Clinical Trial Update: Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

An open-label Phase I dose-escalation study of BAY1143572 in patients with advanced cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BAY1143572

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED